CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

...CONTINUED BELOW

Overview of Severe Asthma

Severe asthma is currently defined by ERS/ATS* Guidelines as"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1:

Severity and control are 2 aspects of asthma. Severe asthma is often uncontrolled."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1

*ERS/ATS=European Respiratory Society and American Thoracic Society

ERS/ATS Guidelines suggest the clinical characteristics of severe asthma include"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1:

  • Poor symptom control (even with maintenance therapy)
  • Frequent severe exacerbations (typically requiring use of oral/systemic corticosteroids)
  • Serious exacerbations (which may result in hospitalization and/or emergency department visits)
  • Airflow limitation (as demonstrated by evidence of lung function impairment)

Impact of severe asthma

Severe Asthma Phenotypes

Current understanding of phenotypes is growing

The notion of distinct phenotypes of severe asthma, each with unique features, is gaining wider acceptance"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"5

Although there are no widely accepted definitions of phenotypes in severe asthma, ERS/ATS Guidelines suggest there may be certain characteristics, such as eosinophilic airway inflammation, that may help in taking a more targeted treatment approach"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1

Overview of Severe Asthma With an Eosinophilic Phenotype

Eosinophilic inflammation

Multiple cell types, including eosinophils, are involved in inflammation. Inflammation is an important component in the pathogenesis of asthma.

  • Eosinophils are white blood cells that are known to play a role in inflammation
  • Interleukin 5 (IL-5) is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils

Eosinophil levels as biomarkers

There are multiple potential biomarkers for eosinophilic inflammation of the airways6

Recent studies have supported blood eosinophil levels as a marker of eosinophilic inflammation in asthma and suggest that blood eosinophil levels can be used as one of the biomarkers to guide therapy in severe asthma7

In practice, blood eosinophil count is a common measurement as part of the complete blood count (CBC) with differential6

   704038R0 June 2016